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Sir; With interest we read the article by 
Kemper et al. [3] on the treatment of acute 
hyperkalaemia in childhood by short-term 
intravenous infusion of salbutamol. Intra­
venous [3, 4, 5] or endotracheal [1, 4, 6] 
administration of salbutamol for the treat­
ment of hyperkalaemia has been reported 
earlier and is increasingly used in practice.
Kemper et al. [3] measured serum 
potassium concentrations at 30, 60, 90 and 
120 min after the intravenous administra­
tion of salbutamol and indeed observed a 
significant and prolonged decrease.
We would like to draw attention to a 
recent paper [2] reporting the results of 
administration of salbutamol in the ba­
boon. It appears that a short-lived increase 
in serum potassium concentrations of about
0.5.mmol/1 is observed, before a prolonged 
decrease occurs, demonstrating an early rise 
in serum potassium, shortly after the ad­
ministration of salbutamol. This hyper- 
kalaemic phase occurred in all six animals 
investigated and was associated with left 
ventricular conduction defects in three of 
them. Since in the human studies serum 
potassium was measured 10 min after the 
administration of salbutamol at the earliest, 
it is not known whether an initial hype- 
rkalaemic phase also occurs in man.
At high serum potassium concentra­
tions, usually the case when salbutamol 
treatment is considered, an eventual in­
crease could trigger serious cardiac dys- 
rythmias, such as ventricular fibrillation. 
We feel that treatment with salbutamol 
should not be advocated until additional 
information about the early response of 
serum potassium concentrations in the 
human is obtained. Since being aware of the 
studies in the baboon, we use only insulin 
and glucose for treating hyperkalaemia.
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Abbreviations HBV  hepatitis B virus -HCV 
hepatitis C virus • HBsAg hepatitis B surface 
antigen
Sir: Down syndrome persons have an 
higher incidence of hepatitis B virus (HBV) 
chronic carriage [4]. Vaccination against 
HBV in these patients has proven effective 
both in adults and children. In the latter age 
group, however, data are still scanty [6]. In
